Liver Cancer Trial, Recruiting (NCT07109440)

Liver Cancer Trial, Recruiting NCT07109440 Sponsor: Jules Bordet Institute Condition: Liver Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07109440 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Liver Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 years or older
People who have cancer that has spread to the liver, confirmed by standard scans such as MRI or FDG PET/CT
People who have either not yet received any cancer treatment, or who have completed chemotherapy given before surgery
People whose medical team has planned surgery to remove the liver metastases (the areas where cancer has spread)
People who are generally well enough to carry out daily activities, based on a standard medical scoring system called ECOG (score of 2 or lower) (confirm with trial site)
People who have given signed written agreement to take part in the study

Who may not be able to join:

People whose liver metastases cannot be surgically removed
Women who are pregnant or breastfeeding
People who have another serious medical condition that, in the opinion of the treating doctor, could interfere with completing the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 02.541.37.81

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07109440

Sponsor: Jules Bordet Institute

Phase: Not Applicable

Status: Recruiting

Condition: Liver Cancer

Trial contact: 02.541.37.81

More information: https://clinicaltrials.gov/study/NCT07109440

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 years or older
People who have cancer that has spread to the liver, confirmed by standard scans such as MRI or FDG PET/CT
People who have either not yet received any cancer treatment, or who have completed chemotherapy given before surgery
People whose medical team has planned surgery to remove the liver metastases (the areas where cancer has spread)
People who are generally well enough to carry out daily activities, based on a standard medical scoring system called ECOG (score of 2 or lower) (confirm with trial site)
People who have given signed written agreement to take part in the study

Who may not be able to join:

People whose liver metastases cannot be surgically removed
Women who are pregnant or breastfeeding
People who have another serious medical condition that, in the opinion of the treating doctor, could interfere with completing the study

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Jules Bordet Institute

Registry

ClinicalTrials.gov

Start date

9 May 2025

Est. completion

1 December 2027

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

The quantification of IHC staining for FAP-expressing CAFs measured in patient-derived tissue specimens; The quantification of FAP expression on FAPI PET/CT (SUVmax, SUVmean, MTV [metabolically active tumor volume], FAPI-TV [FAPI positive tumour load]); correlation between the value of FAPI PET/CT and the percent encapsulated, and the HGP scores (desmoplastic, replacement, pushing) of the liver metastasis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov